Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

TLDR

The study aims to develop preliminary criteria for inactive disease and clinical remission in selected JIA categories and to determine the probability of disease recurrence, with validation underway and plans to extend to other categories. Using a Delphi serial questionnaire followed by a nominal group technique, pediatric rheumatologists generated draft criteria for inactive disease that include absence of arthritis, systemic symptoms, uveitis, normal inflammatory markers, and a best‑score physician global assessment. Consensus defined clinical remission as six continuous months of inactive disease on medication or twelve months off medication, with the off‑medication criteria predicting ≤20 % recurrence over five years, based on input from 130 respondents and 20 conference participants.

Abstract

To develop preliminary criteria for inactive disease and clinical remission for select categories of juvenile idiopathic arthritis (JIA), and to decide what such clinical states should predict in terms of probability of disease recurrence.A Delphi serial questionnaire consensus-formation approach was used initially to gather criteria in use by pediatric rheumatologists (PR) for defining clinical remission in oligoarticular (persistent and extended), rheumatoid factor (RF) positive and negative polyarticular, and systemic JIA. Results from sequential questionnaires provided an agenda for a nominal group technique (NGT) conference to reach consensus on unresolved questions.One hundred and thirty PR from 34 countries responded to the questionnaires and 20 PR from 9 countries attended the conference. Draft criteria for inactive disease include the following: no active arthritis; no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; normal erythrocyte sedimentation rate or C-reactive protein; and a physician's global assessment of disease activity rated at the best score possible for the instrument used. According to consensus vote, 6 continuous months of inactive disease on medication defines clinical remission on medication, while 12 months of inactive disease off all anti-arthritis (and anti-uveitis) medications defines clinical remission off medication. The finalized criteria for remission off medication ideally should predict that a patient has </= 20% probability of disease recurrence within the next 5 years.Using consensus formation techniques, we formulated preliminary criteria for inactive disease and clinical remission on and off medication for use in select categories of JIA. Retrospective validation is in progress; prospective validation will follow. Future efforts will include other categories of JIA.